A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsNeal Van Hoeven, Rhea N. Coler, Christopher B. Fox et al.|PLoS ONE|2016Cited by 33
A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigenNeal Van Hoeven, Rhea N. Coler, Steven R. Wiley et al.|npj Vaccines|2018Cited by 29